Drug
Erwinia asparaginase
Erwinia asparaginase is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_3
2
33%
Ph phase_1
2
33%
Ph phase_2
2
33%
Phase Distribution
2
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(2)
Detailed Status
Active, not recruiting3
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)
Trials by Status
active_not_recruiting350%
completed233%
recruiting117%
Recent Activity
4 active trials
Showing 5 of 6
active_not_recruitingphase_2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03164057
recruitingphase_1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
NCT05292664
active_not_recruitingphase_3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03020030
active_not_recruitingphase_1
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
NCT05192889
completedphase_2
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
NCT01451515
Clinical Trials (6)
Showing 6 of 6 trials
NCT03164057Phase 2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT05292664Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
NCT03020030Phase 3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT05192889Phase 1
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
NCT01451515Phase 2
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
NCT00187083Phase 3
A Study of Children With Refractory or Relapsed ALL
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6